Liraglutide Explored as Add-on Therapy for Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus (T1DM) is a chronic autoimmune disease characterized by the destruction of pancreatic beta cells, leading to absolute insulin deficiency and lifelong dependence on exogenous insulin. Despite advancements in insulin therapy, many patients struggle with achieving optimal glycemic control, managing weight fluctuations, and preventing long-term complications. GLP-1 receptor agonists, like liraglutide, have shown benefits in Type 2 Diabetes by improving glycemic control, promoting weight loss, and reducing cardiovascular risk, but their role in T1DM is less established. This Phase 3 clinical trial aimed to investigate whether adding liraglutide to existing insulin regimens could improve glycemic control, reduce insulin requirements, and offer other metabolic benefits for adults with Type 1 Diabetes.

The provided research record details the comprehensive design and intervention protocols of this Phase 3 clinical trial but does not include any specific results or outcome data. Therefore, quantitative findings such as changes in HbA1c, body weight, insulin dosage, or the incidence of adverse events like hypoglycemia, which were likely primary endpoints, cannot be reported from this abstract. This abstract, while outlining a robust study design for liraglutide in Type 1 Diabetes, does not present any findings on its efficacy or safety. The study's completion in December 2014 suggests that data was collected and analyzed, but these results are not accessible within this specific record. Without outcome data, it is impossible to compare treatment versus control groups quantitatively.